Tetsu Tomonari Yasushi Sato Hironori Tanaka Takahiro Tanaka Tatsuya Taniguchi Msasahiro Sogabe Koichi Okamoto Hiroshi Miyamoto Naoki Muguruma Tetsuji Takayama.
Sorafenib as second‐line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma.
Journal of Gastroenterology and Hepatology. 2020, in press.